Reducing COPD-related Readmissions through Individualized Maintenance Therapy and Increased Patient Engagement

Release Date: April 30, 2018
Expiration Date: April 30, 2019

PRACTITIONER’S EDGESM PANEL

Stanley B. Fiel, MD, FACP, FCCP
Professor of Medicine
Sidney Kimmel Medical College at
Thomas Jefferson University
Philadelphia, Pennsylvania
Regional Chair, Department of Medicine
Atlantic Health System
The deNeufville Professor
Chairman, Department of Medicine
Morristown Medical Center
Morristown, New Jersey

José Luis González, MD
Assistant Professor of Internal Medicine
Department of Internal Medicine
University of Southern California
Primary Care Physician
Department of Primary Care
LAC+USC Medical Center
Los Angeles, California

Program Overview

Hospitals are a critical point of intervention in the care pathway of chronic obstructive pulmonary disease (COPD). Clinicians in this setting must be well-versed in current treatment guidelines, as well as the full spectrum of medications and delivery devices, to provide disease management tailored to the physical and cognitive needs of each patient. Moreover, hospital clinicians also need to be adept at communicating with patients and engaging them in the management of their own disease. Collectively, these measures can significantly reduce symptom severity and risk for future exacerbations, increase physical activity, and improve overall quality of life in patients with COPD. This program will improve the knowledge and competence of clinicians who care for patients with COPD.

Target Audience

This educational initiative has been designed for hospitalists and other healthcare providers involved in the care of patients with COPD.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Identify long-term treatment strategies to reduce hospital readmissions for COPD exacerbations
  • Review the clinical evidence regarding the efficacy and safety of long-acting maintenance regimens for COPD
  • Select medication delivery devices for patients with COPD based upon individual physical and cognitive characteristics
  • Outline a transitional care plan that promotes patient self-management to reduce the risk for future exacerbations and hospital readmissions

Directions to Learner

There are no fees for participating and receiving CME credit for this enduring activity. During the period of April 30, 2018 through April 30, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

Media

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest (COI)

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Stanley B. Fiel, MD, FACP, FCCP
Consulting Fees & Speakers’ Bureau: Gilead Sciences, Inc.
Contracted Research: Vertex Pharmaceuticals.

José Luis González, MD, has no real or apparent conflicts of interest to disclose.

Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Sunovion Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

Disclaimer

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

begin pretest

pre

integrity
 Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from Sunovion Pharmaceuticals, Inc.